[2-(1-ethyl-1H-tetrazol-5-yl)-ethyl]-carbamic acid tert-butyl ester | 847789-38-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: [2-(1-ethyl-1H-tetrazol-5-yl)-ethyl]-carbamic acid tert-butyl ester
• 英文别名: tert-butyl N-[2-(1-ethyltetrazol-5-yl)ethyl]carbamate
• CAS: 847789-38-2
• 化学式: C₁₀H₁₉N₅O₂
• 分子量: 241.293
• InChiKey: IXQRWWAOWARCNC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  81.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  [2-(1-ethyl-1H-tetrazol-5-yl)-ethyl]-carbamic acid tert-butyl ester 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 2-(1-ethyl-1H-tetrazol-5-yl)-ethylamine trifluoroacetate
  参考文献：
  名称：

  [EN] 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES
  [FR] COMPOSES ORGANIQUES

  摘要：

  公开号：

  WO2005021519A3
• 作为产物：
  描述：

  碘乙烷 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 7.17h， 生成 [2-(2-ethyl-2H-tetrazol-5-yl)-ethyl]-carbamic acid tert-butyl ester 、 [2-(1-ethyl-1H-tetrazol-5-yl)-ethyl]-carbamic acid tert-butyl ester
  参考文献：
  名称：

  [EN] 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES
  [FR] COMPOSES ORGANIQUES

  摘要：

  公开号：

  WO2005021519A3

文献信息

• [EN] INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE<br/>[FR] INHIBITEURS DE PHOSPHATIDYLINOSITOL 3-KINASE
  申请人：NOVARTIS AG

  公开号：WO2004096797A1

  公开（公告）日：2004-11-11

  Compounds of formula (I) in free or salt form, wherein R1, R2, R3, and R4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  式(I)中的化合物以自由形式或盐形式存在，其中R1、R2、R3和R4的含义如规范中所示，适用于治疗由磷脂酰肌醇3-激酶介导的疾病。还描述了含有这些化合物的药物组合物以及制备这些化合物的过程。
• Inhibitors of phosphatidylinositol 3-kinase
  申请人：Bruce Ian

  公开号：US20070032487A1

  公开（公告）日：2007-02-08

  Compounds of formula I in free or salt form, wherein R 1 , R 2 , R 3 and R 4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  公式I的化合物以自由或盐形式存在，其中R1、R2、R3和R4的含义如规范中所示，可用于治疗由磷脂酰肌醇3-激酶介导的疾病。还描述了含有这些化合物的制药组合物以及制备这些化合物的过程。
• 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases
  申请人：Bloomfield Graham Charles

  公开号：US20080280871A1

  公开（公告）日：2008-11-13

  in free or salt form, wherein R a , R b , R 2 , R 3 , R 4 and R 5 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  在自由或盐形式中，其中Ra，Rb，R2，R3，R4和R5具有规范中指示的含义，对于治疗由磷脂酰肌醇3-激酶介导的疾病是有用的。还描述了含有该化合物的药物组合物以及制备该化合物的过程。
• INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE
  申请人：BRUCE Ian

  公开号：US20110105535A1

  公开（公告）日：2011-05-05

  Compounds of formula I in free or salt form, wherein R 1 , R 2 , R 3 and R 4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  式I的化合物，无论是自由形式还是盐形式，其中R1、R2、R3和R4的含义如说明书所示，可用于治疗由磷脂酰肌醇3-激酶介导的疾病。还描述了含有这些化合物的制药组合物以及制备这些化合物的过程。
• 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES
  申请人：Bloomfield Graham Charles

  公开号：US20110124624A1

  公开（公告）日：2011-05-26

  Compounds of Formula I: in free or salt form, wherein R a , R b , R 2 , R 3 , R 4 and R 5 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  公式I的化合物：以自由或盐形式存在，其中Ra、Rb、R2、R3、R4和R5的含义如规范中所示，可用于治疗由磷脂酰肌醇3-激酶介导的疾病。还描述了含有这些化合物的制药组合物和制备这些化合物的过程。